AKT1 and cancer: Drugs, such as buparlisib, everolimus, and perifosine, which target the PI3K/Akt/mTOR pathway, have the potential to inhibit survival pathways and induce apoptosis and autophagy in cancer cells, and they have been found to have favorable antitumor efficacies in clinical trials [33].